Fig. 3

OS in previously treated a and treatment-naive b patients in ipilimumab-treated and non-ipilimumab–treated cohorts. IPI ipilimumab, OS overall survival
OS in previously treated a and treatment-naive b patients in ipilimumab-treated and non-ipilimumab–treated cohorts. IPI ipilimumab, OS overall survival